HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases
Authors
Keywords
-
Journal
Translational Oncology
Volume 16, Issue -, Pages 101312
Publisher
Elsevier BV
Online
2021-12-16
DOI
10.1016/j.tranon.2021.101312
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy
- (2020) Bin Tu et al. Frontiers in Cell and Developmental Biology
- Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
- (2020) Hirva Mamdani et al. Frontiers in Cell and Developmental Biology
- Starch nanoparticles for delivery of the histone deacetylase inhibitor CG-1521 in breast cancer treatment
- (2019) Esma Alp et al. International Journal of Nanomedicine
- Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases
- (2019) Himavanth Gatla et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
- (2019) Maria Mrakovcic et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- c-FLIP and CD95 signaling are essential for survival of renal cell carcinoma
- (2019) Tobias Luebke et al. Cell Death & Disease
- Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity
- (2019) Hao Wu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of HDAC6 Attenuates Tumor Growth of Non-Small Cell Lung Cancer
- (2019) Brian Deskin et al. Translational Oncology
- Development of the first small molecule histone deacetylase 6 (HDAC6) degraders
- (2018) Ka Yang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- An oral androgen receptor PROTAC degrader for prostate cancer.
- (2018) Taavi Neklesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer
- (2018) Victor Jeannot et al. JOURNAL OF CONTROLLED RELEASE
- Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
- (2018) Amila Suraweera et al. Frontiers in Oncology
- Combination Effect of Silver Nanoparticles and Histone Deacetylases Inhibitor in Human Alveolar Basal Epithelial Cells
- (2018) Sangiliyandi Gurunathan et al. MOLECULES
- Advancement of NF-κB Signaling Pathway: A Novel Target in Pancreatic Cancer
- (2018) Kartick Pramanik et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin-dependent mechanism
- (2017) Igor Hrgovic et al. EXPERIMENTAL DERMATOLOGY
- Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals)
- (2017) Matthias Schiedel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells
- (2017) Bo Ra You et al. Oncotarget
- Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation
- (2016) Niek GJ Leus et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Therapeutic effects of histone deacetylase inhibitors in a murine asthma model
- (2016) Yuan Ren et al. INFLAMMATION RESEARCH
- The histone deacetylase inhibitor trichostatin A suppresses murine innate allergic inflammation by blocking group 2 innate lymphoid cell (ILC2) activation
- (2016) Shinji Toki et al. THORAX
- Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells
- (2016) Sofia R. Gameiro et al. Oncotarget
- Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor Therapy
- (2016) Fatima el Bahhaj et al. Theranostics
- HDACs and HDAC Inhibitors in Cancer Development and Therapy
- (2016) Yixuan Li et al. Cold Spring Harbor Perspectives in Medicine
- Histone deacetylase inhibitor-polymer conjugate nanoparticles for acid-responsive drug delivery
- (2015) Iza Denis et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Iron Complexation to Histone Deacetylase Inhibitors SAHA and LAQ824 in PEGylated Liposomes Can Considerably Improve Pharmacokinetics in Rats
- (2015) Yan Wang et al. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
- Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation
- (2015) K.V. Woan et al. Molecular Oncology
- Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response
- (2015) Afua Adjeiwaa Mensah et al. Oncotarget
- Epigenetic Modulation with HDAC Inhibitor CG200745 Induces Anti-Proliferation in Non-Small Cell Lung Cancer Cells
- (2015) Sung-Min Chun et al. PLoS One
- HDAC inhibitors and immunotherapy; a double edged sword?
- (2015) Michiel Kroesen et al. Oncotarget
- Biocompatibility and biodistribution of suberoylanilide hydroxamic acid loaded poly (DL-lactide-co-glycolide) nanoparticles for targeted drug delivery in cancer
- (2014) Renu Sankar et al. BIOMEDICINE & PHARMACOTHERAPY
- Histone deacetylase inhibitors and cell death
- (2014) Jing Zhang et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
- (2014) Sridurga Mithraprabhu et al. Epigenetics
- Targeting Histone Deacetylases for Cancer Therapy: From Molecular Mechanisms to Clinical Implications
- (2014) Zhiming Li et al. International Journal of Biological Sciences
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Panobinostat: a review of trial results and future prospects in multiple myeloma
- (2014) Edward N Libby et al. Expert Review of Hematology
- Histone deacetylase inhibitors
- (2013) Marije Slingerland et al. ANTI-CANCER DRUGS
- Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors
- (2013) Madeleine SQ Kortenhorst et al. Epigenetics
- Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease
- (2013) Peter J. Barnes JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Histone Deacetylase Inhibitors Potentiate Vesicular Stomatitis Virus Oncolysis in Prostate Cancer Cells by Modulating NF- B-Dependent Autophagy
- (2013) L. Shulak et al. JOURNAL OF VIROLOGY
- The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity
- (2013) David M. Woods et al. MELANOMA RESEARCH
- Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer
- (2013) Darryl T. Martin et al. Nanomedicine-Nanotechnology Biology and Medicine
- Expression level of histone deacetylase 2 correlates with occurring of chronic obstructive pulmonary diseases
- (2012) Yiqing Qu et al. MOLECULAR BIOLOGY REPORTS
- Mitochondrial Apoptosis and FAK Signaling Disruption by a Novel Histone Deacetylase Inhibitor, HTPB, in Antitumor and Antimetastatic Mouse Models
- (2012) Jiunn-Min Shieh et al. PLoS One
- Deciphering the Molecular Events Necessary for Synergistic Tumor Cell Apoptosis Mediated by the Histone Deacetylase Inhibitor Vorinostat and the BH3 Mimetic ABT-737
- (2011) A. P. Wiegmans et al. CANCER RESEARCH
- Vorinostat-Induced Apoptosis in Mantle Cell Lymphoma Is Mediated by Acetylation of Proapoptotic BH3-Only Gene Promoters
- (2011) S. Xargay-Torrent et al. CLINICAL CANCER RESEARCH
- Lung cancer and its association with chronic obstructive pulmonary disease: update on nexus of epigenetics
- (2011) Isaac K Sundar et al. CURRENT OPINION IN PULMONARY MEDICINE
- Unknown
- (2011) Charles Dinarello et al. MOLECULAR MEDICINE
- Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma
- (2010) Yuan-Ling Liu et al. Autophagy
- Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells
- (2010) Li-Yuan Bai et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Liposomes loaded with histone deacetylase inhibitors for breast cancer therapy
- (2010) Giorgia Urbinati et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Histone Deacetylase Inhibitors Suppress Inflammatory Activation of Rheumatoid Arthritis Patient Synovial Macrophages and Tissue
- (2010) Aleksander M. Grabiec et al. JOURNAL OF IMMUNOLOGY
- Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity
- (2010) Yamanegi ONCOLOGY REPORTS
- Anti-Tumor Effect in Human Lung Cancer by a Combination Treatment of Novel Histone Deacetylase Inhibitors: SL142 or SL325 and Retinoic Acids
- (2010) Shaoteng Han et al. PLoS One
- Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung
- (2010) Yoshihiro Minamiya et al. TUMOR BIOLOGY
- Enhancing the apoptotic and therapeutic effects of HDAC inhibitors
- (2009) Ailsa J. Frew et al. CANCER LETTERS
- The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation
- (2009) Daniela Carlisi et al. EUROPEAN JOURNAL OF CANCER
- Histone deacetylase inhibitors: Potential in cancer therapy
- (2009) P.A. Marks et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL
- (2009) James Symanowski et al. Journal of Thoracic Oncology
- Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate
- (2009) A Poggi et al. LEUKEMIA
- HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer
- (2009) A López-Soto et al. ONCOGENE
- Synergistic effect of trichostatin A and 5-aza-2′-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: A proteomic study
- (2009) Daniela Cecconi et al. PROTEOMICS
- Effects of nickel, chromate, and arsenite on histone 3 lysine methylation
- (2009) Xue Zhou et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- SIRT1, an Antiinflammatory and Antiaging Protein, Is Decreased in Lungs of Patients with Chronic Obstructive Pulmonary Disease
- (2008) Saravanan Rajendrasozhan et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Role of HDAC2 in the Pathophysiology of COPD
- (2008) Peter J. Barnes Annual Review of Physiology
- Acetylation Is Indispensable for p53 Activation
- (2008) Yi Tang et al. CELL
- Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer
- (2008) A. Van Den Broeck et al. CLINICAL CANCER RESEARCH
- Transcriptional Modulation Using HDACi Depsipeptide Promotes Immune Cell-Mediated Tumor Destruction of Murine B16 Melanoma
- (2008) Takashi Murakami et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
- (2008) A. Miyanaga et al. MOLECULAR CANCER THERAPEUTICS
- Functions of natural killer cells
- (2008) Eric Vivier et al. NATURE IMMUNOLOGY
- Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells
- (2007) Shan Gao et al. LEUKEMIA RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now